REGENXBIO Inc. RGNX
At closeNov 4, 2026, 4:48 PM EST
After hours · Nov 4, 4:48 PM ET
- YTD
- -46.46%
- 1 year
- -33.30%
- Market cap
- 508.96M
- Revenue (ttm)
- 84.33M
- Profit margin
- -283.19%
- EPS (ttm)
- -3.78
- Shares out
- 49.55M
- Forward P/E
- -6.83
- YTD return
- -46.46%
- 1-year return
- -33.30%
- Volume
- 1.14M
- Avg volume
- 1.36M
- Open
- 7.72
- Previous close
- 7.63
- Day's range
- 7.48 – 7.96
- 52-week range
- 5.46 – 16.19
- Beta
- 1.23
- Analysts
- Strong Buy
- Price target
- 37.64 (+388.1%)
6M -1.52 (-16.49%)
Key statistics
- Enterprise value
- 267.88M
- PEG ratio
- 0.00
- Price / sales
- 4.34
- Price / book
- 1.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -16.30%
- Free cash flow
- -95.26M
- Total cash
- 255.46M
- Total debt
- 145.81M
- Return on equity
- -71.87%
- Short % of float
- 13.88%
- 50-day average
- 9.58
- 200-day average
- 13.24
Analyst view
Consensus: strong buy
- Target (low)
- 22.00
- Target (mean)
- 37.64
- Target (high)
- 52.00
- Strong buy5
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.11.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -1.16 | -1.17 | -0.01 | -0.86% |
| Aug 1, 2024 | Jun 1, 2024 | -1.29 | -1.05 | +0.24 | +18.60% |
| May 8, 2024 | Mar 1, 2024 | -1.28 | -1.38 | -0.10 | -7.81% |
| Feb 27, 2024 | Dec 1, 2023 | -1.27 | -1.43 | -0.16 | -12.60% |
| Nov 8, 2023 | Sep 1, 2023 | -1.44 | -1.41 | +0.03 | +2.08% |
| Aug 2, 2023 | Jun 1, 2023 | -1.26 | -1.66 | -0.40 | -31.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | RBC Capital | reit | Outperform | Outperform |
| Nov 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 20, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 7, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 22, 2024 | Chardan Capital | main | Buy | Buy |
| Sep 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- regenxbio.com
News
Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High? 
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates 
REGENXBIO to Participate in Stifel 2026 Healthcare Conference 
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy? 
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights 
Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR) 
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy 
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript 
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 
Full Transcript: Regenxbio Q2 2026 Earnings Call
Your note
Sign in to keep a note on RGNX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAN MITCHELL | Chief Financial Officer | Stock Award(Grant) | Sep 15, 2024 | 58,869 |
| CHRISTMAS PATRICK J. II | Officer | Stock Award(Grant) | Jul 31, 2024 | 172,205 |
| DANOS OLIVIER | Officer | Stock Award(Grant) | Jul 31, 2024 | 185,083 |
| KARABELAS ARGERIS N | Director | Conversion of Exercise of derivative security | Sep 30, 2024 | 11,286 |
| MIGAUSKY GEORGE V | Director | Stock Award(Grant) | May 30, 2024 | 11,286 |
| MILLS KENNETH THOMAS | Director | Conversion of Exercise of derivative security | Aug 7, 2024 | 444,351 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.85% | 8,844,466 | 65.27M | Sep 29, 2024 |
| Redmile Group, LLC | 9.88% | 4,892,902 | 36.11M | Sep 29, 2024 |
| Vanguard Group Inc | 8.82% | 4,368,991 | 32.24M | Sep 29, 2024 |
| State Street Corporation | 5.62% | 2,782,883 | 20.54M | Sep 29, 2024 |
| JP Morgan Chase & Company | 5.00% | 2,477,311 | 18.28M | Sep 29, 2024 |
| Morgan Stanley | 2.72% | 1,349,876 | 9.96M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 5.86% | 2,902,939 | 21.42M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.83% | 1,400,445 | 10.34M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.39% | 1,183,646 | 8.74M | Oct 30, 2024 |
| JP Morgan Small Cap Growth Fund | 2.35% | 1,162,623 | 8.58M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.78% | 880,902 | 6.50M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.48% | 735,639 | 5.43M | Sep 29, 2024 |